One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease-Reference-Cited by-同舟云学术

One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease

Published:2016-04-15 Issue:4 Volume:11 Page:e0152812
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Najafian Behzad,Tøndel Camilla,Svarstad Einar,Sokolovkiy Alexey,Smith Kelly,Mauer Michael

Funder

Genzyme

National Institute of Neurological Disorders and Stroke

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes;RJ Desnick;J Lab Clin Med,1973

2. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males;KD MacDermot;J Med Genet,2001

3. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy;BL Thurberg;Kidney Int,2002

4. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease;DP Germain;J Am Soc Nephrol,2007

5. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial;M Banikazemi;Ann Intern Med,2007

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reconceptualizing podocyte damage in Fabry disease: new findings identify α-synuclein as a putative therapeutic target;Kidney International;2024-02

2. Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases;Kidney International;2024-01

3. Cardiomyocyte Globotriaosylceramide Accumulation in Adult Male Patients with Fabry Disease and IVS4 + 919G>A GLA Mutation is Progressive with Age and Correlates with Left Ventricular Hypertrophy and Reduced Left Ventricular Ejection Fraction;2023-12-11

4. Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study;Frontiers in Medicine;2023-09-01

5. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy;Journal of Clinical Investigation;2023-06-01